The cancer diagnostics developer raised $7.4m in the Wuxi Pharmatech-backed round, and has now secured more than $15m in overall funding.
US-based cancer diagnostics company Avelas Biosciences has closed the second tranche of a $7.4m series B round from backers including healthcare research company WuXi PharmaTech.
WuXi PharmaTech, which invested through its WuXi PharmaTech Investments subsidiary, participated in the round alongside Avalon Ventures, Torrey Pines Investment and additional undisclosed investors.
Avelas’ lead product candidate, AVB-620, is a diagnostic tool that could deliver a real-time cancer diagnosis in the form of a luminous map, which would enable surgeons to make more thorough…
